SCR-M030

SCR-M030 is an innovative, potential first-in-class trispecific T-cell engager (TCE) designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Developed by Simcere Zaiming, the molecule simultaneously targets two tumor-associated antigens, prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of the prostate 1 (STEAP1), alongside the CD3 receptor on T cells. The drug utilizes an avidity-optimized architecture, binding STEAP1 with high affinity and PSMA with moderate affinity to prioritize engagement with double-positive tumor cells, thereby addressing the inter- and intratumoral heterogeneity often seen with PSMA-only therapies. Additionally, it features a deliberately attenuated CD3 binding affinity to minimize the risk of cytokine release syndrome (CRS). Preclinical studies have demonstrated potent antitumor activity in xenograft models and compatibility with both intravenous and subcutaneous administration.